Journal ArticleDOI
Bioavailabilty of phenytoin
P. Tammisto,K. Kauko,M. Viukari +2 more
Reads0
Chats0
About:
This article is published in The Lancet.The article was published on 1976-01-31. It has received 22 citations till now. The article focuses on the topics: Randomized controlled trial.read more
Citations
More filters
Journal ArticleDOI
Clinical pharmacokinetics of phenytoin.
TL;DR: The metabolism of Phenytoin to the major metabolite, 5-(p-hydroxyphenyl)-5-(phenylhydantoin, is saturable, giving rise to a non linear dose-serum concentration relationship, so the dose range compatible with a therapeutic serum concentration is narrow within subjects, and monitoring serum concentrations is of particular value in dosage tailoring.
Journal ArticleDOI
Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.
TL;DR: It is important to examine the question of whether generic substitution may pose problems for patients with epilepsy, and whether there should be safeguards to ensure that both physician and patient are informed when generic substitution occurs.
Journal ArticleDOI
Phenytoin Prodrugs III: Water-Soluble Prodrugs for Oral and/or Parenteral Use
TL;DR: Various bioreversible derivatives of phenytoin, a poorly water soluble and erratically absorbed drug after both oral and parenteral dosing, confirmed that a number of the derivatives did indeed behave as prodrugs.
Journal ArticleDOI
Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs
Emilio Perucca,Fiorenzo Albani,Giuseppe Capovilla,Bernardo Dalla Bernardina,Roberto Michelucci,Gaetano Zaccara +5 more
TL;DR: It is concluded that generic AEDs meeting current regulatory criteria for bioequivalence represent a valuable choice in the management of epilepsy by allowing a substantial reduction of treatment costs, particularly in patients initiating monotherapy or adjunctive treament and in those with persistent seizures.
Journal ArticleDOI
Is Generic Prescribing Acceptable in Epilepsy
TL;DR: Whatever arguments might be put forward supporting brand name or generic prescribing, there are strong reasons for recommending tight control on the consistency of anticonvulsant drugs, both generic and proprietary.
References
More filters
Journal Article
Studies on 5, 5'-diphenylhydantoin (dilantin) in animals and man.
TL;DR: In the rat, highest concentrations were found in the liver and fat, followed in order of decreasing concentration by the heart, spleen, kidney, lung and skeletal muscle, and red blood cells were found to contain Dilantin in approximately the same concentration as plasma.
Journal ArticleDOI
Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas-liquid chromatography.
TL;DR: A gas-liquid Chromatographic method for the simultaneous determination of phenobarbital, primidone and diphenylhydantoin in human plasma following therapeutic doses has been developed and has the advantages of specificity, sensitivity and simple derivative formation.
Journal ArticleDOI
Serum-phenytoin levels in management of epilepsy
Alan Richens,Andrew Dunlop +1 more
TL;DR: A nomogram which permits the clinician, given a single, accurate, steady-state phenytoin level, to adjust the dosage to achieve the desirable therapeutic concentration of 60 or 80 mumol per litre (15 or 20 mug.)
Journal ArticleDOI
Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin.
TL;DR: The plasma levels of phenytoin (diphenylhydantoin, DPH) in epileptic patients were significantly higher after treatment with either of two preparations containing the sodium salt of DPH, than after treatment of the same dose of the free acid, in both short and long term studies.